AviaraDx discovers, develops, and commercializes new molecular diagnostic tests in oncology, enabling physicians to personalize cancer treatment through better understanding of the molecular biology underlying a patient’s tumor. Our tests improve the classification of cancer, support physicians to provide their patients with a more specific prognosis and individual risk assessment, and will eventually provide information critical to predict treatment response to a given therapeutic regimen.

AviaraDx offers diagnostic tests to qualified physicians or laboratories through its certified CLIA laboratory service operations. The company's first three diagnostic test offerings, based on its proprietary technologies used in molecular classification of cancers, are:

• Aviara CancerTYPE ID^SM - for improved cancer classification, especially in patients diagnosed with metastatic cancer where the origin is uncertain or unknown.
• Aviara H/I^SM for assessment of endocrine resistance and risk of recurrence in certain breast cancers.
• Aviara MGI^SM for objective measurement of tumor grade and prediction of chemosensitivity in ER+ breast tumors

All tests are real time, RT-PCR based, assays that are compatible with readily available, formalin-fixed, paraffin embedded (FFPE) needle core biopsies, excisional biopsies and/or surgical samples.